DEFLORIA is developing AJA001, a full-spectrum botanical hemp extract, as a novel oral therapeutic for Autism Spectrum Disorder (ASD). The company leverages proprietary hemp extracts and drug development expertise to advance this cannabinoid drug through clinical trials toward FDA approval. This work aims to provide the first standardized botanical medicine addressing significant unmet needs in the ASD patient population.
Funding
$750K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current therapeutic options for Autism Spectrum Disorder (ASD) are limited, with only two FDA-approved medications available, both associated with significant adverse effects. This presents an unmet need for alternative treatments that can effectively manage ASD symptoms with a favorable safety profile.
Solution
DEFLORIA is developing AJA001, a novel, full-spectrum botanical hemp extract designed to alleviate symptoms of Autism Spectrum Disorder. This candidate leverages advanced drug development expertise and scientifically validated botanical medicine, aiming to provide a new therapeutic option for the autism community. AJA001 is derived from proprietary hemp extracts and is standardized through rigorous pharmaceutical development processes. The company's approach focuses on harnessing the therapeutic potential of CBD and other cannabinoids, supported by the entourage effect, to deliver healing benefits without the psychoactive implications. DEFLORIA is advancing AJA001 through clinical trials with the goal of achieving FDA approval.
Target Audience
The primary target audience includes individuals diagnosed with Autism Spectrum Disorder, their caregivers, and healthcare providers seeking novel therapeutic interventions.
Features
- AJA001: A full-spectrum botanical hemp extract formulated for Autism Spectrum Disorder symptom management.
- Proprietary hemp extract sourcing from Charlotte's Web, a recognized leader in the industry.
- Advanced drug development expertise from Ajna BioSciences, focusing on pharmaceutical standardization.
- Focus on the entourage effect, utilizing multiple cannabinoids and terpenes for enhanced therapeutic potential.
- Development pathway targeting FDA approval as an oral-systemic botanical drug.
- Potential for patent protection upon FDA approval, establishing first-mover advantage.